Abstract
Omega-3 Polyunsaturated Fatty Acids for Treatment of Nonalcoholic Fatty Liver Disease: A Possible Case for Personalized Therapy
Highlights
One interesting finding was the observed changes in lysophospholipids, revealing significant changes in oleic, linoleic, and arachidonic acid but not DHA-containing lyso-PLs
The authors conclude that DHA likely attenuated MUFA synthesis by decreasing fatty acid synthase (FASN), ATP-citrate lyase (ACL) and SCD1 expression
Their results suggest that DHA-containing diets regulate hepatic 16:0, 18:1,n-7, and 18:1,n-9 content by controlling multiple genes involved in DNL and MUFA synthesis as well as the availability of substrates required for DNL
Summary
One interesting finding was the observed changes in lysophospholipids (lyso-PLs), revealing significant changes in oleic, linoleic, and arachidonic acid but not DHA-containing lyso-PLs. Changes in hepatic content of these metabolites were associated with a corresponding decline in the NASH gene expression markers (i.e., MCP1, CD68, ProCOL1A1, NOX2, SCD1 and TLR4). The authors conclude that DHA likely attenuated MUFA synthesis by decreasing fatty acid synthase (FASN), ATP-citrate lyase (ACL) and SCD1 expression.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
